New and Developing Therapeutic Strategies for ESCC and Gastric/GEJ Adenocarcinoma

This discussion highlights several emerging therapeutic approaches that are shaping future directions in advanced gastric and gastroesophageal junction (GEJ) cancers. The discussion reviews the growing development of antibody–drug conjugates (ADCs), including those directed at HER2 and Claudin 18.2, which are currently being evaluated in ongoing clinical trials. Early-phase efforts with Claudin 18.2-targeted CAR T-cell therapies are also noted, with emphasis on the preliminary nature of these studies and the need for further clinical validation. Additionally, the segment addresses targeted agents such as bemarituzumab, an FGFR2b-directed monoclonal antibody that has demonstrated activity in FGFR2b-overexpressing gastric cancer when combined with chemotherapy. Together, these investigational strategies reflect a broader shift toward molecularly selected treatment approaches. While data continue to evolve, these research programs represent important avenues that may help inform future management options in advanced gastric and GEJ cancers.